Welcome to our dedicated page for OSR Health SEC filings (Ticker: OSRHW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OSR Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OSR Health's regulatory disclosures and financial reporting.
OSR Holdings, Inc. received notice from Nasdaq that it has been granted an additional 180-day period, until August 31, 2026, to regain compliance with the Nasdaq minimum bid price rule requiring a bid of at least $1.00 per share.
The company was first notified on September 5, 2025, that its stock had traded below $1.00 for 30 consecutive business days and initially had until March 4, 2026, to regain compliance. Nasdaq granted more time because OSR Holdings meets all other Nasdaq Capital Market listing standards, including market value of publicly held shares.
If the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days during this new period, Nasdaq will confirm that the company has regained compliance. OSR Holdings plans to monitor its share price and consider available options to meet Nasdaq’s bid price requirement.
OSR Holdings, Inc. completed the acquisition of South Korea-based medical device company Woori IO Co., Ltd. (WORIO) on January 26, 2026 through a share exchange under the Korean Commercial Act. OSR Holdings’ subsidiary OSR Holdings Co., Ltd. (OSRK) acquired all issued and outstanding WORIO shares, making WORIO a wholly owned subsidiary of OSRK and an indirect subsidiary of OSR Holdings.
Each WORIO share was exchanged for 0.948832 OSRK shares, and OSRK issued an aggregate of 84,338 new shares in exchange for 88,891 WORIO shares. The transaction was completed using equity in the subsidiary, and no OSR Holdings common stock was issued. OSR Holdings plans to file any required financial statements for this acquisition by amendment within 71 days.
OSR Holdings, Inc. filed an 8-K reporting the results of a shareholder vote on director elections. Several nominees received overwhelming affirmative votes and were elected, while two nominees received large negative vote totals and were not elected. For example, Jun Chul Whang received 13,321,765 votes for and 3,926 against and was elected. Seng Chin Mah received 13,321,806 for and 3,885 against and was elected. Two nominees, Jin Whan Park (451,054 for; 12,874,637 against) and Phil Geon Lee (451,095 for; 12,874,596 against), were not elected. The filing supplies vote counts and final election outcomes for each listed nominee.